340 filings
Page 5 of 17
8-K
ft3zlrj
27 Jan 22
Zymeworks Announces Proposed Public Offering
5:00pm
424B5
hkxkam2d 4m21dyt8gr2
27 Jan 22
Prospectus supplement for primary offering
4:56pm
424B5
3ragueuoo814c5
26 Jan 22
Prospectus supplement for primary offering
4:26pm
8-K
kijkxpu
19 Jan 22
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2022
4:51pm
8-K
wwdyo
18 Jan 22
Zymeworks Reports Inducement Grant Under New York Stock Exchange Listed Company Manual Rule
6:19am
8-K
idhct
6 Jan 22
Zymeworks to Present at 40th Annual J.P. Morgan Healthcare Conference
4:15pm
8-K
9c9rr5 nu
5 Jan 22
Zymeworks Names Biotechnology Industry Leader Kenneth Galbraith as Chair and CEO to Succeed Dr. Ali Tehrani
5:11pm
8-K
01ocjkdx nqltcqhv7d
9 Dec 21
Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in Asia in Collaboration with BeiGene and Associated Milestone Payment
4:16pm
8-K
xb2fupx
9 Dec 21
Zanidatamab Data Presented at the San Antonio Breast Cancer Symposium
12:00am
8-K
f74c9z7bocu3rwtt3otn
1 Dec 21
Zymeworks Announces Second Janssen Bispecific Antibody to Begin Clinical Development Utilizing Azymetric™ and EFECT™ Therapeutic Platforms
4:16pm
8-K
5ay2q jc6e3qe
19 Nov 21
Zymeworks Announces Abstract for Zanidatamab in Late-Line HER2-Positive
4:33pm
8-K
pc30q4o8kzr
9 Nov 21
Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line
5:05pm
8-K
n0dzxfjr6
8 Nov 21
Zymeworks to Present at Upcoming Investor Conferences
5:01pm
8-K
zv55772v0oq710zj2o1g
3 Nov 21
Zymeworks Reports 2021 Third Quarter Financial Results
4:19pm
8-K
4v8cs8ppbtgpz1tz5
26 Oct 21
Zymeworks Announces Webcast to Present HERIZON-GEA-01 Pivotal Trial Design and Zanidatamab Commercial Strategy in Gastrointestinal Cancers
4:16pm
8-K
9n55dkik
5 Oct 21
Regulation FD Disclosure
4:06pm
8-K
sqgslrq41e
1 Oct 21
Entry into a Material Definitive Agreement
5:25pm
424B5
v1yrod
1 Oct 21
Prospectus supplement for primary offering
5:10pm
S-3ASR
216vllx6rli6
1 Oct 21
Automatic shelf registration
4:45pm